Related Experiment Video

Updated: Jan 2, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K

Mechanistic insight of cyclin-dependent kinase 5 in modulating lung cancer growth

G M Shazzad Hossain Prince1, Tsung-Ying Yang2, Ho Lin3

  • 1Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.

The Chinese Journal of Physiology
|December 4, 2019
PubMed

Insights

Cyclin-dependent kinase 5 (Cdk5) plays a key role in lung cancer progression by regulating tumor suppressor genes and immune checkpoints. Inhibiting Cdk5 offers a promising therapeutic strategy for combating lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Lung cancer involves complex signaling and cytoskeletal changes.
  • Cyclin-dependent kinase 5 (Cdk5), primarily known in the central nervous system, is increasingly recognized for its role in cancer.
  • Aberrant Cdk5 expression correlates with poor survival in lung cancer patients.

Purpose of the Study:

  • To review the multifaceted roles of Cdk5 in lung cancer.
  • To elucidate the underlying mechanisms by which Cdk5 influences lung cancer progression.
  • To highlight the therapeutic potential of targeting Cdk5 in lung cancer.

Main Methods:

  • Literature review of studies investigating Cdk5 in lung cancer.
  • Analysis of Cdk5's involvement in key cellular processes.
  • Examination of therapeutic strategies targeting Cdk5.

Main Results:

  • Cdk5 regulates critical pathways in lung cancer, including tumor suppressor genes, carcinogenesis, cytoskeletal remodeling, and immune checkpoints.
  • Targeting Cdk5 through pharmacological inhibitors, siRNA, or CRISPR-Cas9 demonstrates therapeutic benefits.
  • Cdk5's aberrant expression is linked to adverse patient outcomes.

Conclusions:

  • Cdk5 is a significant modulator of lung cancer progression and patient survival.
  • Targeting Cdk5 presents a viable therapeutic avenue for lung cancer treatment.
  • Further research into Cdk5's mechanisms is warranted to optimize therapeutic strategies.
Keywords:
CDK5DNA damagePD-L1cytoskeletal remodelinglung cancertumor suppressor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
133.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K